Vernakalant - Correvio Pharma

Drug Profile

Vernakalant - Correvio Pharma

Alternative Names: Brinavess; Kynapid; MK-6621; RSD-1235; vernakalant (IV); vernakalant (oral); Vernakalant-hydrochloride

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiome Pharma
  • Developer Aspen Pharmacare; ATCO Laboratories; Cipher Pharmaceuticals; Correvio Pharma
  • Class Anisoles; Antiarrhythmics; Cyclohexanes; Pyrrolidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation

Most Recent Events

  • 23 Oct 2018 Correvio Pharma plans to re-submit NDA to the US FDA for Atrial fibrillation in the second quarter of 2019
  • 05 Sep 2018 Preliminary efficacy and adverse events data from the post-authorisation SPECTRUM study in Atrial fibrillation released by Correvio Pharma
  • 14 Aug 2018 Launched for Atrial fibrillation in United Arab Emirates (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top